Funding for this research was provided by:
National Institute of Mental Health (MH107426, MH119172, MH086785, R21 MH091309, U19 MH108206, R01 MH100173)
Received: 16 September 2021
Accepted: 26 September 2022
First Online: 29 October 2022
: Informed consent/assent was obtained from all guardians and participants after procedures were fully explained and the opportunity to ask questions offered. The protocol was approved and overseen by the Yale University IRB.
: All data shown in figures, tables, and text are presented in aggregated or anonymized form. Permission to share anonymized participant information was provided by all guardians and participants.
: James C. McPartland consults with Customer Value Partners, Bridgebio, Determined Health, and BlackThorn Therapeutics, has received research funding from Janssen Research and Development, serves on the Scientific Advisory Boards of Pastorus and Modern Clinics, and receives royalties from Guilford Press, Lambert, and Springer. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.